Seattle Genetics, Inc. – Lymphoma, Non-Hodgkin

Submitted By:

Published Date:

January 25, 2020

The purpose of this study is to provide the option of brentuximab vedotin treatment to
eligible patients in studies SGN35-005 and C25001

Rare Disease:

Hodgkin’s disease